Autologous CD8+ SLC45A2-specific T Lymphocytes (MD Anderson Cancer Center)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAutologous CD8+ SLC45A2-specific T Lymphocytes (MD Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionSolute Carrier Family 45 Member 2 modulators
TargetsSolute Carrier Family 45 Member 2
Therapy Area/IndicationsUveal melanomaLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsUveal melanomaLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A